ERBB2 and neoplasm: In mice, xenografts established from a patient with a HER2+ tumor with an acquired D769Y mutation in HER2 following progression on trastuzumab-based therapy were resistant to trastuzumab and lapatinib but sensitive to neratinib, which induced durable tumor shrinkage.